Last reviewed · How we verify
CABENUVA
At a glance
| Generic name | CABENUVA |
|---|---|
| Sponsor | ViiV Healthcare |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
Common side effects
- Injection site reactions
- Pyrexia
- Fatigue
- Headache
- Musculoskeletal pain
- Nausea
- Sleep disorders
- Dizziness
- Rash
Serious adverse events
- Acute hepatitis B
- Hepatitis A
- Diarrhea
Key clinical trials
- Combined Injectable Treatment for HIV and OUD (PHASE2)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2,PHASE3)
- A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA (PHASE3)
- Kuwa Free! - Live Free! (NA)
- Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.) (PHASE4)
- WePrEP: Developing a PrEP Shared Decision-making Tool for Transgender Women (NA)
- Cabenuva Injection Tracking in CHORUS (NA)
- Implementing Cabenuva in Arkansas HIV Programs (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CABENUVA CI brief — competitive landscape report
- CABENUVA updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI